TRPV4 and glioblastoma: The results from flow cytometry assays and CCK-8 assays showed that TRPV4 agonist (GSK1, 10 nM) and antagonist (GSK2, 100 nM) did not impact the cell cycle or apoptosis of GBM cells (Fig. S1E-G).